IMAPAC’s 3rd Biologics Korea gathering to bring together over 150 leading industry players

Feb. 19, 2014 - PRLog -- For the third consecutive year, IMAPAC will bring together players from the Korean and international biologics and biosimilars industry at the region’s MOST TARGETED biologics and biosimilars platform - 3rd Annual Biologics World Korea 2014 - taking place from 22-24 April 2014 in Seoul, Korea.

The biologics landscape in South Korea is evolving fast, but although the Korean government has made a number of investments to support the local biologics industry, players have mainly focused on biosimilar drugs. The subject in question now is whether or not Korea can successfully transition from biosimilars to innovative biologics. Although their strong base in biosimilars capabilities can provide a solid technical foundation, there are many aspects of the innovative RnD market that will not develop without focused attention.

“I strongly believe that Korea biotech industry will move forward fast to become a global CMO hub which results in manufacture of own products later,” says Dr. YongJick Kim, Consultant and Former President, Manufacturing and Technical Operations, Celltrion, Korea, who will be speaking at the Biologics World Korea 2014 event on overcoming current manufacturing challenges, ensuring sustainable growth, and overcoming competition from neighbouring countries.

In recognition of current market needs, and different information and the knowledge requirements of players from various biologic backgrounds, Biologics World Korea 2014 will feature 4 separate conferences focused on Biosimilars and Biobetters, BioProcessing, BioAnalytical and BioPartnerships.  Each conference will cover specific domain knowledge to stimulate direct relevance, practicality and problem solving.

Key speaking faculty at the 3^rd Annual Biologics World Korea 2014 include:

Paul Coleman PhD, Chief Executive Officer, Hanwha Biologics, Korea
Daniel D. Adams PhD, Executive Chairman and Global Head of Business Development, Protein Sciences Corporation, USA
YongJick Kim, PhD, President, Manufacturing and Technical Operations, Celltrion, Korea
Yariv Hefez, VP Strategic Development, Business Development, Portfolio Management and Partnering (Biosimilars), Merck Serono, Switzerland
Binhui Ben Ni, PhD, Head of Scouting and Partnering, Sanofi-Aventis, China
George Wang, President and CEO, Mab-Venture Biopharmaceuticals Co.Ltd, China
Chong-Hwan Jonathan Chang, PhD, President, New Drug Development Center (NDDC), Korea
Racho Jordanov, President and CEO, JHL Biotech, Taiwan
Jin San Yoo PhD, CEO, Pharmabcine, Korea
Gregory Tewalt, PhD, Vice President Quality and Compliance, Samsung Biologics, Korea
Lee Cheng Liu, PhD, President and CEO, Erigenix Inc, Taiwan
Chris Zhisheng Chen,PhD, Senior Vice President and Chief Technology Officer, Biologics Service, WuXi App Tec, China
Jeremy Caudill, Global Vice President, Business Development, Samsung BioLogics, Korea
Sang Hoon Lee PhD, Senior Vice President, Hanwha Biologics, Korea
Yi Huang PhD, Head, Department of Protein Sciences, Huabo Biopharm Co.Ltd, China
Sun Lei, PhD, Director Manufacture, AutekBio, China
Sukhui Kim, Director of Validation, Samsung Biologics, Korea
Byeong Doo Song PhD, President, Scripps Korea Antibody Institute, Korea
Madi R. Madiyalakan PhD, Chief Executive Officer, Quest Pharma Tech Inc, Canada
May Wei, Global Regulatory Stratergist, Bayer Health Care, China
Jong Shin Yoo, PhD, Director, Korea Basic Science Institute, Korea
Changlin Dou PhD, Chief Technology Officer, Luye Pharmacy Group, China
Huiguo (Forrest) Hu, Head of International Business, Shanghai CP Guojian Pharmaceuticals Co Ltd, China
Suk Mok Lee, PhD, Principal Investigator, Scripps Korea Antibody Institute, South Korea
Gregory J. Glover, Principal, Pharmaceutical Law Group PC, USA
Jeffrey Su, PhD, Chief Scientific Officer, Cytovance Biologics Inc, USA

Hear what attendees have to say about past Biologics World Korea events:

“The conference was nice as a whole, compact and it was a very interactive meeting.” - Antonio SJ Lee, Associate Director, Business Development and R&D Strategy, Medipost, Korea

“Good diversity of conference programme and well planned.” - Dan Adams, Executive Chairman, Protein Sciences. USA

“High quality presentations, excellent organization. One of the best conferences I attended” - Richard Somberg, Strategic Collaboration Manager, Promega, USA

For more information on the upcoming event, please contact Natasha Jiandani on Natasha.jiandani@imapac.com or call +65-6493-1871.

About IMAPAC

IMAPAC is a social enterprise headquartered in Singapore that creates business conferences with a socially beneficial cause. For every attendee to an IMAPAC conference, IMAPAC ensures that a child from a developing country gets to go to school for a year.